Vizgen raises $37M to bring Merscope platform to market

By The Science Advisory Board staff writers

April 7, 2021 -- Vizgen has closed $37 million in financing to support the commercialization and manufacturing of its Merscope platform.

Merscope is the company's integrated platform for generating multiplexed error-robust fluorescence in situ hybridization (MERFISH) measurements. In March, the company announced that Merscope will become commercially available in the summer of 2021.

The series B financing was co-led by Novalis LifeSciences and current investor Northpond Ventures.

Vizgen launches integrated Merscope in situ imaging platform
Vizgen has launched its Merscope platform, a multiplexed, error-robust, single-cell in situ transcriptomic imaging technology.
Vizgen debuts accelerator lab in the U.S.
Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.

Copyright © 2021

Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter